Future studies with cancer outcomes data will be highly relevant for better understanding risk of aggressive prostate cancer among AA men, as well as for targeting communities and individuals who may be more likely to experience benefit from PSA testing. This evidence concerns the gene KLK3 and Familial prostate cancer.